MarketPulse

ALS treatment

3 articles
BenzingaBenzinga··Prnewswire

BrainStorm Charts Recovery Path With $2M Funding as NurOwn Advances to Pivotal ALS Trial

BrainStorm Cell Therapeutics reported $10.3M net loss for 2025 while securing $2M financing and advancing NurOwn into Phase 3b ALS study following FDA clearance.
BCLIfinancial resultsprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Clene Inc.

Clene Maps Out 2026 Regulatory Path for ALS Candidate CNM-Au8

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.
CLNNFDA approvalclinical trial
BenzingaBenzinga··Prnewswire

Brainstorm Cell Raises $1M Through Private Placement Above Current Valuation

Brainstorm Cell raised $1M via private placement at $0.60/share, above market price. Funds support Phase 3b ALS therapy trials and regulatory efforts.
BCLIprivate placementstem cell therapy